0

Category: CMHC

Cardiometabolic Health Congress

FDA Grants Approval for Two New Insulin Therapies

Two new insulin formulations were recently granted FDA approval: Tresiba® (insulin degludec), a long-acting insulin analog that can be administered once daily any time of day, and Ryzodeg®, a combination of insulin degludec and rapid-acting insulin aspart that is taken once or twice per day with any main meal. Both are indicated for adults with type 1 and 2 diabetes.

The approvals add to a growing list of insulin options for patients with diabetes. Toujeo® (insulin glargine U300) was approved earlier this year and Afrezza®, the only inhaled insulin available in the US, reached pharmacies in February. Learn more about these newest options and how they can help you customize your patients’ insulin regimens at the 10th Annual CMHC. On Friday, October 23, Dr. Matthew Riddle will chair the symposium, “Paving the Way to Patient Acceptance, Adherence and Satisfaction: The Role of Next-Generation Insulin Therapies,” and Dr. Anne Peters will chair “The Evolution of Insulin Therapy: New Developments in Treatment, Technology, and Methods of Administration” on Saturday, October 24. Read more

First Fully Mobile Continuous Glucose Monitor Gets FDA Approval

The US FDA has just approved the first and only fully mobile continuous glucose monitoring system for both adults and children as young as 2 years of age. The system sends glucose information in real time directly to an app on iOS-enabled devices, such as the iPhone, using Bluetooth technology. (Android applications are expected early next year.) The Dexcom G5 Mobile CGM System allows for up to 5 “followers,” such as parents or other caregivers, to remotely monitor the patient’s glucose levels and receive alerts about readings of concern.

To learn more on innovations such as these, join us at #CMHC 2015 on Saturday, October 24 for “Advances in Diabetes Technology,” to be presented during the Diabetes Management session by expert faculty speaker Anne L. Peters, MD.

Read more here.